Adalimumab Concept

Vocabulary Service

MeSH

Overview

subject area of

2018 American College of Rheumatology/National Psoriasis Foundation Guideline for the Treatment of Psoriatic Arthritis Journal Articles
Adalimumab for Treatment of Moderate to Severe Chronic Plaque Psoriasis of the Hands and Feet Journal Articles
Adalimumab in the Treatment of Psoriasis: Pooled Efficacy and Safety Results from Three Pivotal Studies Journal Articles
Adalimumab versus infliximab for the treatment of moderate to severe ulcerative colitis in adult patients naïve to anti-TNF therapy: An indirect treatment comparison meta-analysis Journal Articles
American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network 2015 recommendations for the treatment of ankylosing spondylitis and nonradiographic axial spondyloarthritis Journal Articles
An open-label, prospective cohort pilot study to evaluate the efficacy and safety of etanercept in the treatment of moderate to severe plaque psoriasis in patients who have not had an adequate response to adalimumab. Journal Articles
Anti-TNFα therapy in immune-mediated subfertility: State of the art Journal Articles
Bell's palsy in a patient receiving adalimumab for Crohn's disease Journal Articles
Biologic survival. Journal Articles
Biosimilar Policies and Their Impact on Market Penetration of Adalimumab, Etanercept and Infliximab: A Policy Synthesis and Descriptive Analysis in 13 OECD Countries. Journal Articles
COMMENTARY: Should Anti‐TNF‐α Therapy be Offered to Patients with Infertility and Recurrent Spontaneous Abortion?* Journal Articles
Canada's Study of Adherence Outcomes in Patients Receiving Adalimumab: 3-year Results From the COMPANION Study Journal Articles
Canadian cost-utility analysis of initiation and maintenance treatment with anti-TNF-α drugs for refractory Crohn's disease Journal Articles
Comparative Effectiveness of Biologics for Endoscopic Healing of the Ileum and Colon in Crohn's Disease Conferences
Comparative effectiveness of higher adalimumab maintenance therapy versus standard dose in anti‐tumor necrosis factor experienced Crohn's disease patients: A propensity‐score matched cohort analysis Journal Articles
Comparative efficacy of golimumab, infliximab, and adalimumab for moderately to severely active ulcerative colitis: a network meta-analysis accounting for differences in trial designs Journal Articles
Cost per remission and cost per response with infliximab, adalimumab, and golimumab for the treatment of moderately-to-severely active ulcerative colitis Journal Articles
Decision Support Tool Identifies Ulcerative Colitis Patients Most Likely to Achieve Remission With Vedolizumab vs Adalimumab Journal Articles
Delayed Ustekinumab and Adalimumab Responders Have Similar Outcomes as Early Responders in Biologic-Naïve Crohn's Disease Journal Articles
End of induction patient reported outcomes predict clinical remission and endoscopic improvement with vedolizumab and adalimumab in ulcerative colitis Journal Articles
Etanercept for patients with psoriasis who did not respond or who lost their response to adalimumab or infliximab Journal Articles
Higher adalimumab maintenance regimen is more effective than standard dose in anti-TNF experienced Crohn’s disease patients Journal Articles
Higher adalimumab serum levels do not increase the risk of adverse events in patients with inflammatory bowel disease Journal Articles
Immunotherapies in Dermatologic Disorders Journal Articles
Impact of the Adalimumab Patient Support Program's Care Coach Calls on Persistence and Adherence in Canada: An Observational Retrospective Cohort Study Journal Articles
Improvement in health utility among patients with rheumatoid arthritis treated with adalimumab (a human anti-TNF monoclonal antibody) plus methotrexate Journal Articles
Improvement in serum eosinophilia is observed in clinical responders to ustekinumab but not adalimumab in inflammatory bowel disease. Journal Articles
Increased Expression of Interleukin-13 Receptor in Ileum Associated With Nonresponse to Adalimumab in Ileal Crohn’s Disease Journal Articles
Letter: comparative safety and efficacy of infliximab vs. adalimumab in Crohn's disease – should one consider disease location? Authors’ reply Journal Articles
Long-Term Outcomes of Early vs Delayed Responders to Vedolizumab and Adalimumab: A Post Hoc Analysis of the VARSITY Study Journal Articles
Meta‐analysis: peri‐operative anti‐TNFα treatment and post‐operative complications in patients with inflammatory bowel disease Journal Articles
Norms-based assessment of patient-reported outcomes associated with adalimumab monotherapy in patients with ankylosing spondylitis. Journal Articles
Patient outcomes after anti TNF-α drugs for Crohn’s disease Journal Articles
Practical Understanding of Mean Percent Psoriasis Area and Severity Index Reduction for Biologics Journal Articles
Pragmatic pharmacoeconomic analyses by using post-market adverse drug reaction reports: an illustration using infliximab, adalimumab, and the Canada vigilance adverse reaction database Journal Articles
Predictors of Clinical Remission to Placebo in Clinical Trials of Crohn’s Disease Journal Articles
Proactive therapeutic drug monitoring of biologic drugs in adult patients with inflammatory bowel disease, inflammatory arthritis, or psoriasis: a clinical practice guideline. Journal Articles
Safety and effectiveness of adalimumab in a clinical setting that reflects Canadian standard of care for the treatment of rheumatoid arthritis (RA): Results from the CanACT study Journal Articles
Safety and efficacy of bimekizumab through 2 years in patients with moderate-to-severe plaque psoriasis: longer-term results from the BE SURE randomized controlled trial and the open-label extension from the BE BRIGHT trial Journal Articles
The economics of adalimumab for ulcerative colitis Journal Articles
The efficacy and safety of either infliximab or adalimumab in 362 patients with anti‐TNF‐α naïve Crohn's disease Journal Articles
Treatment of severe facial psoriasis with adalimumab. Journal Articles
Use of Modified Multiplier of the Simple Endoscopic Score for Crohn's Disease Endoscopic Improvement Thresholds Enhances Effect Size Differentiation Between Adalimumab Versus Placebo: A Post Hoc Analysis of the EXTEND Trial. Journal Articles
Ustekinumab versus adalimumab for induction and maintenance therapy in biologic-naive patients with moderately to severely active Crohn's disease: a multicentre, randomised, double-blind, parallel-group, phase 3b trial Journal Articles
Vedolizumab and Adalimumab in Biologic-Naïve Ulcerative Colitis: Comparison of Patient-Level Clinical Trial Data and VARSITY for Week 6 Clinical Remission Journal Articles
Week 2 Adalimumab Levels Predict Short-term Clinical Remission in Patients With Inflammatory Bowel Disease Journal Articles